Medicare Part D coverage · istradefylline · RxCUI 2199026
istradefylline 20 MG Oral Tablet [Nourianz]
Per the CMS 2026 Part D formulary file, istradefylline 20 MG Oral Tablet [Nourianz] is covered by 160 Medicare Part D plans (3.2% of enrollable products), averaging Tier 3.9, with prior authorization required on 46.2% of covering formularies.
- 3.2%
- Plan coverage
- 160
- Plans covering
- T3.9
- Avg tier
- 46.2%
- Prior auth required
What the CMS Formulary Data Shows for istradefylline 20 MG Oral Tablet [Nourianz]
Per the CMS 2026 Part D formulary file, istradefylline 20 MG Oral Tablet [Nourianz] (RxNorm concept RXCUI 2199026, generic name istradefylline) appears on 13 distinct formulary files spanning 160 Medicare Part D plan offerings - 3.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.9.
Real-world access to istradefylline 20 MG Oral Tablet [Nourianz] depends on utilization management as much as tier placement: 46.2% of covering formularies require prior authorization. 0% require step therapy. 53.8% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 3,546 Part D beneficiaries filled istradefylline 20 MG Oral Tablet [Nourianz] in 2023, with total plan-and-beneficiary spending of $49,718,992 and an average per-beneficiary annual cost of $14,021.15. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry istradefylline 20 MG Oral Tablet [Nourianz] today.
Coverage Details
- Formularies covering
- 13
- Plans covering
- 160
- Coverage rate
- 3.2%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 46.2% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 53.8% of formularies
2023 Medicare Spending
- Beneficiaries
- 3,546
- Total spending
- $49,718,992
- Avg per beneficiary
- $14,021.15
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering istradefylline 20 MG Oral Tablet [Nourianz]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| CareAdvantage (HMO D-SNP) | SAN Mateo Health Commission | T2 | Yes | $0 | CA |
| CalOptima Health OneCare Complete (HMO D-SNP) | Orange County Health Authority | T2 | No | $0 | CA |
| Medicare BlueEssential (PPO) | Excellus Health Plan, Inc. | T5 | Yes | $0 | NY |
| Medicare BlueActive (PPO) | Excellus Health Plan, Inc. | T5 | Yes | $0 | NY |
| Medicare BlueVital (PPO) | Excellus Health Plan, Inc. | T5 | Yes | $0 | NY |
| Univera SeniorChoice Basic (HMO) | Excellus Health Plan, Inc. | T5 | Yes | $0 | NY |
| Univera SeniorChoice Extra (HMO) | Excellus Health Plan, Inc. | T5 | Yes | $0 | NY |
| Medicare Blue Choice Core (HMO) | Excellus Health Plan, Inc. | T5 | Yes | $0 | NY |
| Univera Medicare Dual (HMO D-SNP) | Excellus Health Plan Community Care LLC | T5 | Yes | $0 | NY |
| Medicare Blue Dual (HMO D-SNP) | Excellus Health Plan Community Care LLC | T5 | Yes | $0 | NY |
| Kaiser Permanente Senior Advantage LA, Orange Co. (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
| Kaiser Permanente Senior Advantage Enhanced Solano (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
| Kaiser Permanente Senior Advantage Inland Empire (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
| Kaiser Permanente Sr Adv Enhanced Marin San Mateo (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
| Kaiser Permanente Senior Advantage Ventura (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
| Kaiser Permanente Senior Advantage Enhanced Kern (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
| Kaiser Permanente Senior Advantage Basic Kern (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
| Kaiser Permanente Senior Advantage San Diego (HMO) | Kaiser Foundation HP, Inc. | T5 | No | $0 | CA |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is istradefylline 20 MG Oral Tablet [Nourianz] covered by Medicare Part D?
Yes, istradefylline 20 MG Oral Tablet [Nourianz] is covered by 160 Medicare Part D plans (3.2% of all Part D formularies).
What tier is istradefylline 20 MG Oral Tablet [Nourianz] on Medicare Part D plans?
istradefylline 20 MG Oral Tablet [Nourianz] averages Tier 3.9 across Part D plans, ranging from Tier 1 to Tier 5.
Does istradefylline 20 MG Oral Tablet [Nourianz] require prior authorization?
46.2% of Part D formularies require prior authorization for istradefylline 20 MG Oral Tablet [Nourianz]. Step therapy: 0%. Quantity limits: 53.8%.
How much does Medicare spend on istradefylline 20 MG Oral Tablet [Nourianz]?
In 2023, total Medicare Part D spending on istradefylline 20 MG Oral Tablet [Nourianz] was $49,718,992, covering 3,546 beneficiaries. The average spend per beneficiary was $14,021.15.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- lofexidine 0.18 MG Oral Tablet 46.2% PA
- isotretinoin 10 MG Oral Capsule [Accutane] 46.3% PA
- promethazine hydrochloride 50 MG Rectal Suppository [Promethegan] 46.3% PA
- hydroxyzine pamoate 25 MG Oral Capsule 46.1% PA
- isotretinoin 20 MG Oral Capsule [Accutane] 46.4% PA
- isotretinoin 40 MG Oral Capsule [Accutane] 46.6% PA